Skip to main content

Advertisement

SpringerLink
Log in

Effect of topical prostaglandins on the biomechanics and shape of the cornea

  • Cornea
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the effect of topical prostaglandin (PG) eyedrops on the biomechanics and shape of the cornea.

Methods

Consecutive patients with primary open-angle glaucoma who had been treated with the same anti-glaucoma PG (114 eyes, 57 patients) or β-blocker (36 eyes, 18 patients) eyedrops in 1 eye alone for more than 3 months at Inouye Eye Hospital or Miyata Eye Hospital. The biomechanical properties of the cornea were measured using a Corvis ST device (Oculus, Wetzlar, Germany). Corneal tomography was measured with a Casia 1 or 2 (Tomey Corp., Nagoya, Japan). The biomechanical parameters and tomographic features of the cornea were compared between PG-treated eyes, β-blocker-treated eyes, and contralateral eyes using a mixed-effect model adjusted for intraocular pressure and corneal thickness and a linear model adjusted for age, sex, intraocular pressure, and corneal thickness.

Results

The PG-treated eyes had a significantly smaller applanation 1 time, the highest concavity radius, and a larger deformation amplitude than the contralateral eyes. Also, the PG-treated eyes had a significantly smaller applanation 1 time and applanation 2 velocity but a larger peak distance than the β-blocker-treated eyes. There were no significant differences in any of the Casia parameters between the PG-treated eyes and the contralateral eyes.

Conclusion

The results of this study suggest that topical PG makes biochemical changes to the cornea but does not alter its shape.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

A1:

First applanation

A2:

Second applanation

HC:

Highest concavity

logMAR:

Logarithm of the minimum angle of resolution

MMP:

Matrix metalloproteinase

PG:

Prostaglandin

POAG:

Primary open-angle glaucoma

SITA:

Swedish Interactive Threshold Algorithm

TIMP:

Tissue inhibitors of metalloproteinase

References

  1. Toris CB, Gabelt BT, Kaufman PL (2008) Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 53(Suppl1):S107–S120

    Article  Google Scholar 

  2. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD (1997) Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 38:2772–2780

    CAS  PubMed  Google Scholar 

  3. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN (1996) Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 15:869–875

    Article  CAS  Google Scholar 

  4. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN (1997) Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 38:2214–2223

    CAS  PubMed  Google Scholar 

  5. Honda N, Miyai T, Nejima R et al (2010) Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch Ophthalmol 128:466–471

    Article  CAS  Google Scholar 

  6. Lopilly Park HY, Kim JH, Lee KM, Park CK (2012) Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea. Exp Eye Res 94:13–21

    Article  CAS  Google Scholar 

  7. Wu N, Chen Y, Yu X, Li M, Wen W, Sun X (2016) Changes in corneal biomechanical properties after long-term topical prostaglandin therapy. PLoS One 11:e0155527

    Article  Google Scholar 

  8. Meda R, Wang Q, Paoloni D, Harasymowycz P, Brunette I (2017) The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma. Br J Ophthalmol 101:120–125

    Article  Google Scholar 

  9. Lema I, Duran JA (2005) Inflammatory molecules in the tears of patients with keratoconus. Ophthalmology 112:654–659

    Article  Google Scholar 

  10. Shetty R, Ghosh A, Lim RR et al (2015) Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A. Invest Ophthalmol Vis Sci 56:738–750

    Article  CAS  Google Scholar 

  11. Hallahan K, Dupps W Jr, Roberts C (2018) Deformation response to an air puff: clinical methods. In: Roberts C, Dupps WJ, Downs C (eds) Biomechanics of the eye. Kugler Publications, Amsterdam

    Google Scholar 

  12. Ali NQ, Patel DV, McGhee CN (2014) Biomechanical responses of healthy and keratoconic corneas measured using a noncontact Scheimpflug-based tonometer. Invest Ophthalmol Vis Sci 55:3651–3659

    Article  Google Scholar 

  13. Francis M, Pahuja N, Shroff R et al (2017) Waveform analysis of deformation amplitude and deflection amplitude in normal, suspect, and keratoconic eyes. J Cataract Refract Surg 43:1271–1280

    Article  Google Scholar 

  14. Elham R, Jafarzadehpur E, Hashemi H et al (2017) Keratoconus diagnosis using Corvis ST measured biomechanical parameters. J Curr Ophthalmol 29:175–181

    Article  Google Scholar 

  15. Wang W, Du S, Zhang X (2015) Corneal deformation response in patients with primary open-angle glaucoma and in healthy subjects analyzed by Corvis ST. Invest Ophthalmol Vis Sci 56:5557–5565

    Article  Google Scholar 

  16. Mietz H, Esser JM, Welsandt G et al (2003) Latanoprost stimulates secretion of matrix metalloproteinases in Tenon fibroblasts both in vitro and in vivo. Invest Ophthalmol Vis Sci 44:5182–5188

    Article  Google Scholar 

  17. Catalan-Lopez S, Cadarso-Suarez L, Lopez-Raton M, Cadarso-Suarez C (2018) Corneal biomechanics in unilateral keratoconus and fellow eyes with a Scheimpflug-based tonometer. Optom Vis Sci 95:608–615

    Article  Google Scholar 

  18. Amano S, Nakai Y, Ko A, Inoue K, Wakakura M (2008) A case of keratoconus progression associated with the use of topical latanoprost. Jpn J Ophthalmol 52:334–336

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to acknowledge Dr. Toshihito Furukawa (Biostatistical Research Co., Ltd., Tokyo) for the statistical analyses and Editage (www.editage.jp) for English language editing services.

Author information

Authors and Affiliations

  1. Inouye Eye Hospital, 4-3 Kandasurugadai, Chiyoda-ku, Tokyo, 101-0062, Japan

    Shiro Amano & Kenji Inoue

  2. Miyata Eye Hospital, Miyakonojo, Japan

    Ryohei Nejima & Kazunori Miyata

Authors
  1. Shiro Amano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryohei Nejima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazunori Miyata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shiro Amano.

Ethics declarations

Conflict of interest

Dr. Amano has received research grants from Santen Pharmaceutical and speaker honoraria from Santen Pharmaceutical, Senju Pharmaceutical, Alcon, AMO, HOYA, and Otsuka Pharmaceutical. Dr. Nejima has received speaker honoraria from Santen Pharmaceutical, Senju Pharmaceutical, Alcon, and Nitoh Medic. Dr. Inoue has received research grants from Santen Pharmaceutical, Alcon, Senju Pharmaceutical, Allergan Japan, Teijin Pharma Limited, IQVIA Services Japan, Mayo Corporation, and Eli Lilly Japan and speaker honoraria from Santen Pharmaceutical, Otsuka Pharmaceutical, Senju Pharmaceutical, Kowa Pharmaceutical, Allergan Japan, Novartis Pharma, and Wakamoto Pharmaceutical. Dr. Miyata has received research grants from Santen Pharmaceutical, Senju Pharmaceutical, Alcon, Wakamoto Pharmaceutical, HOYA, Shionogi Pharmaceutical, Novartis Pharma, Sucampo Pharma LLC, Bayer, Chugai Pharmaceutical, and Kissei Pharmaceutical and speaker honoraria from Santen Pharmaceutical, Senju Pharmaceutical, Alcon, AMO, Otsuka Pharmaceutical, Wakamoto Pharmaceutical, HOYA, Kowasoyaku, Chuosangyo, Tomey, Staar Japan, Alcon Pharma, and Japan Tissue Engineering.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of Inouye Eye Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amano, S., Nejima, R., Inoue, K. et al. Effect of topical prostaglandins on the biomechanics and shape of the cornea. Graefes Arch Clin Exp Ophthalmol 257, 2213–2219 (2019). https://doi.org/10.1007/s00417-019-04435-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-019-04435-7

Keywords

Search

Navigation